Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
MinuteCE®
Safety Considerations and AE Monitoring for Trial Participation With Combination Regimens
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
MinuteCE®
Getting Trial-Ready: Matching Patients to Frontline Studies of KRAS G12C Inhibitors
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
MinuteCE®
From Biopsy to Results: Building a Reflex-Ready Testing Workflow
Gerard A. Silvestri MD, MS
0.75 program credits
- Gerard A. Silvestri MD, MS
0.75 program credits
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
MinuteCE®
Navigating the Evidence: Emerging Frontline Combination Strategies in KRAS G12C NSCLC
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
News
Emactuzumab in TGCT: Primary Results From the Phase 3 TANGENT Trial
A.J. Gelderblom, MD, PhD
- A.J. Gelderblom, MD, PhD
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
CME/CE
SOHO 2026 Debrief: Translating the Latest CLL Data Into Community Practice Decisions
Jennifer R. Brown, MD, PhD
0.50 credits
- Jennifer R. Brown, MD, PhD
0.50 credits
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
On the Frontlines of Metastatic Breast Cancer
First-Line ADCs in Metastatic Triple-Negative Breast Cancer
Alexandria May, PharmD, BCPS; Heather McArthur, MD, MPH, FASCO
- Alexandria May, PharmD, BCPS
- Heather McArthur, MD, MPH, FASCO
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Clinician's Roundtable
From Evidence to Practice: Advances in Malignant Pleural Effusion Management
Nicholas Pastis, MD
- Nicholas Pastis, MD

Medical News

Medical News
Proteinuria Reporting Signals With ICI–VEGFR-TKI Regimens in RCC
11/02/2026
Read more
Medical News
Single-Scan Renal TIAC Modeling During Lu-177 PSMA-617 Therapy
10/30/2026
Read more
Medical News
Chatbots Show Similar Overall Quality in Testicular Cancer Answers
10/30/2026
Read more
Medical News
Natera MCED Assay Receives FDA Breakthrough Device Designation
10/28/2026
Read more

CME/CE

KRAS G12C Biology: Why Is This Mutation Different?
KRAS G12C Biology: Why Is This Mutation Different?
MinuteCE®
KRAS G12C Biology: Why Is This Mutation Different?
Timothy F. Burns, MD, PhD
0.75 program credits
- Timothy F. Burns, MD, PhD
0.75 program credits
MinuteCE®
Oral SERDs and PROTACs in ER+/HER2− mBC: Testing Smarter, Treating Better
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 credits 4 episodes
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits

Clinical Practice

MinuteCE®
Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 credits 6 episodes
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
MinuteCE®
The Pulmonology-Oncology Handoff: What Are the Potential Failure Points?
Timothy F. Burns, MD, PhD; Gerard A. Silvestri MD, MS
0.75 program credits
- Timothy F. Burns, MD, PhD
- Gerard A. Silvestri MD, MS
0.75 program credits
Biomarker Testing After Progression in HR+/HER2- mBC
Biomarker Testing After Progression in HR+/HER2- mBC
On the Frontlines of Metastatic Breast Cancer
Biomarker Testing After Progression in HR+/HER2- mBC
Alexandria May, PharmD, BCPS; Adam Brufsky, MD, PhD
- Alexandria May, PharmD, BCPS
- Adam Brufsky, MD, PhD
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
Solange Peters, MD, PhD
0.50 credits
- Solange Peters, MD, PhD
0.50 credits

Programs

What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
CME/CE
What the Evidence Demands: A Clinician’s Decision Framework for LR-MDS Anemia Management
Amer Zeidan, MBBS; Guillermo Garcia-Manero, MD
0.50 credits
- Amer Zeidan, MBBS
- Guillermo Garcia-Manero, MD
0.50 credits
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
On the Frontlines of Non-Small Cell Lung Cancer
Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer
Ryan Quigley; Alexander Drilon, MD
- Ryan Quigley
- Alexander Drilon, MD
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Project Oncology®
Sequencing Decisions in R/R LBCL: CAR T-Cell Therapy and Bispecific Antibodies
Steve Jackson, PharmD; Paolo F. Caimi, MD
- Steve Jackson, PharmD
- Paolo F. Caimi, MD
- Narendranath Epperla, MD, MS
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
Project Oncology®
Exploring Sub-Ablative Radiation to Modulate Immunity in Mesothelioma
John Cho, MD, PhD, FRCPC
- John Cho, MD, PhD, FRCPC